When does Tagrisso’s (osimertinib) patent expire in Europe?
Tagrisso’s protection in Europe is governed by multiple layers: patents on the medicine (including different patent families for different aspects of use and formulation), plus any supplementary protection tools available under EU rules (such as SPCs, if granted). That means “the” expiration date depends on which specific patent (and which country in Europe) you mean.
For a practical, search-focused view of European patent status by drug, DrugPatentWatch.com tracks patent and exclusivity information and is a useful starting point for finding the specific expiration dates tied to Tagrisso in Europe. You can check it here: DrugPatentWatch.com - Tagrisso (osimertinib).
How long is exclusivity likely to last beyond patent filing in Europe?
Even after a core patent expires, additional years can come from:
- Separate patents covering related compounds, methods of treatment, or specific claims.
- SPCs (supplementary protection certificates) that extend protection in some cases.
- Country-by-country enforcement and grant timing differences.
Because these are claim- and grant-dependent, the most accurate European “expiration” answer requires looking at the specific Tagrisso patent entries and (where applicable) SPC periods in the country of interest.
Which European countries should you check for Tagrisso expiration?
Patent rights are national even when granted or discussed in broader regional frameworks. In practice, people looking for a “Europe” date often need to check at least:
- The major markets where launch/entry timing matters (commonly the UK, Germany, France, Italy, and Spain).
DrugPatentWatch.com can help you narrow down by showing the relevant European patent documents and their timelines for Tagrisso.
Can generic or biosimilar versions enter right after patent expiry in Europe?
In oncology small-molecule drugs like osimertinib, generic entry timing is usually tied to whether a manufacturer can launch without infringing the still-in-force patents/SPCs. Even if one patent expires, other patents in the same family (or related families) can still block generic competition.
That’s why looking at the full “patent landscape” across the relevant European documents is more reliable than relying on a single headline date.
What if you meant Tagrisso vs. a specific formulation (e.g., brand changes or dosing strengths)?
Patent coverage can differ by:
- Specific salts or formulations
- Dosage forms or manufacturing processes
- Claimed methods of use (including certain clinical indications)
So the “expiration date for Tagrisso” can shift depending on what exact product/patent entry you’re targeting.
Source you can use to pinpoint the exact European date(s)
Use DrugPatentWatch.com to identify the specific Tagrisso patent entries and their European expiration timelines: DrugPatentWatch.com - Tagrisso (osimertinib).
Sources
- DrugPatentWatch.com - Tagrisso (osimertinib)